Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications
about
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptorsSynthesis and purine receptor affinity of 6-oxopurine nucleosides and nucleotides containing (N)-methanocarba-pseudoribose ringsNeoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosidesIdentification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor.Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.Adenosine receptor agonists: from basic medicinal chemistry to clinical development.Partial agonists for A(3) adenosine receptors.Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches.Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptors.Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists."Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonistsChapter 13. A3 Adenosine Receptors.Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA.Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonistsSynthesis and pharmacological characterization of [(125)I]MRS1898, a high-affinity, selective radioligand for the rat A(3) adenosine receptor.Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists.Functional selectivity of adenosine receptor ligandsThe A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.Selective Phosphorylation of South and North-Cytidine and Adenosine Methanocarba-Nucleosides by Human Nucleoside and Nucleotide Kinases Correlates with Their Growth Inhibitory Effects on Cultured Cells.Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.
P2860
Q28344116-09D44B39-1635-487D-99CE-2E33506D0039Q28347088-A53BB0FF-90ED-4550-A9D6-169DD0E0B19EQ28364092-089ADDEC-5D49-4DBA-8619-BBBEA270DC5AQ34118123-A40413CA-D05A-4E30-AFB0-4D9BEBD66F0AQ35029175-1C66CB90-CFF8-4045-9010-6D42AB6F86A2Q35602688-71014FAA-A4BA-4BB6-82ED-7655C86F5865Q35743739-D2A7F864-54EA-4541-8EB1-FA44B25441B8Q35825817-30A27B07-B067-4998-AD3A-E2BBFC9348E5Q36021597-1A63CBBD-EF65-42E0-B8F4-C9811E45B0A5Q36110665-1AB1E566-60AF-49BC-BDFE-5D2EE16C10B1Q36146803-8BE4D261-519D-4E28-A85C-47B979DCEFDCQ36294009-7BFD7250-4618-4F4A-8ACB-D801CDBF4041Q36327179-FFAB4C7E-28A1-48AF-832F-2FDDBF916EA1Q36342540-94E3731E-9918-4E4C-9AC8-26DAD0053D92Q36725267-F5BE9668-78B6-413C-B9B9-7C671218D69DQ36738027-F004FA64-A35D-4DF1-AD5B-A19CD36B7DC7Q36996182-E5B432A8-1CAB-4BDA-9BCB-8FEAA006D879Q37122033-46F76F33-02E4-46C7-87DB-3B0CF68EDEF7Q37291606-988157A0-5AB2-4BD6-9AA4-96148AEBCEE4Q37636314-2D34B6AF-4D9B-426C-AA7F-3CAAF39BA847Q37637798-B2E9F7A3-A1D3-402A-883B-AD40BBFF5C38Q37872220-1428C428-73B0-46A9-935B-EA517298700FQ37957791-FBA5F562-0AA3-4BEB-8D47-769AECA5E9C2Q38853830-06438C50-7021-4B4B-8AB6-1C9459CB72A0Q48172109-E1AC80EC-FF0F-47F8-B8F3-63E3345A209C
P2860
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@ast
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@en
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@nl
type
label
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@ast
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@en
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@nl
prefLabel
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@ast
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@en
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@nl
P2093
P2860
P1476
Ring-Constrained (N)-methanoca ...... ide and 2'-deoxy modifications
@en
P2093
P2860
P304
P356
10.1016/S0960-894X(01)00213-X
P407
P577
2001-05-21T00:00:00Z